T
Thomas Fetsch
Researcher at University of Münster
Publications - 50
Citations - 2406
Thomas Fetsch is an academic researcher from University of Münster. The author has contributed to research in topics: Signal-averaged electrocardiogram & Myocardial infarction. The author has an hindex of 19, co-authored 49 publications receiving 1722 citations. Previous affiliations of Thomas Fetsch include University of Hamburg & Helsinki University of Technology.
Papers
More filters
Journal ArticleDOI
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation
Paulus Kirchhof,A. John Camm,Andreas Goette,Axel Brandes,Lars Eckardt,Arif Elvan,Thomas Fetsch,Isabelle C. van Gelder,Doreen Haase,Laurent M. Haegeli,Frank Hamann,Hein Heidbuchel,Gerhard Hindricks,Josef Kautzner,Karl-Heinz Kuck,Lluís Mont,G. André Ng,Jerzy Rekosz,Norbert Schoen,Ulrich Schotten,Anna Suling,Jens Taggeselle,Sakis Themistoclakis,Eik Vettorazzi,Panos Vardas,Karl Wegscheider,Stephan Willems,Harry J. Crijns,Günter Breithardt +28 more
TL;DR: Early rhythm-control therapy was associated with a lower risk of cardiovascular outcomes than usual care among patients with early atrial fibrillation and cardiovascular conditions.
Journal ArticleDOI
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial
Thomas Fetsch,Peter Bauer,Rolf Engberding,Hans P. Koch,Jan Lukl,Thomas Meinertz,Michael Oeff,Ludger Seipel,Hans Joachim Trappe,Norbert Treese,Günter Breithardt +10 more
TL;DR: Anti-arrhythmic treatment after DC cardioversion of persistent AF significantly decreases the recurrence rates of persistence AF compared to placebo with superiority of quinidine plus verapamil compared to sotalol.
Journal ArticleDOI
Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
Andreas Goette,Norbert Schön,Paulus Kirchhof,Günter Breithardt,Thomas Fetsch,Karl Georg Häusler,Helmut U. Klein,Gerhard Steinbeck,Karl Wegscheider,Thomas Meinertz +9 more
TL;DR: One year of ARB therapy per se does not reduce the number of AF episodes in patients with documented paroxysmal AF without structural heart disease, as reported in the ANTIPAF trial.
Journal ArticleDOI
Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation
Paulus Kirchhof,Karl Georg Haeusler,Benjamin F. Blank,Joseph de Bono,David J. Callans,Arif Elvan,Thomas Fetsch,Isabelle C. Van Gelder,Philip J. Gentlesk,Massimo Grimaldi,Jim Hansen,Gerhard Hindricks,Hussein R. Al-Khalidi,Tyler Massaro,Lluís Mont,Jens Cosedis Nielsen,Georg Nölker,Jonathan P. Piccini,Jonathan P. Piccini,Tom De Potter,Daniel Scherr,Ulrich Schotten,Sakis Themistoclakis,Derick Todd,Johan Vijgen,Luigi Di Biase +25 more
TL;DR: Continuous apixaban is safe and effective in patients undergoing atrial fibrillation ablation at risk of stroke with respect to bleeding, stroke, and cognitive function.
Journal ArticleDOI
Personalized management of atrial fibrillation
Paulus Kirchhof,Guenter Breithardt,Etienne Aliot,Sana Al Khatib,Stavros Apostolakis,Angelo Auricchio,Christophe Bailleul,Jeroen J. Bax,Gerlinde Benninger,Carina Blomström-Lundqvist,Lucas V.A. Boersma,Giuseppe Boriani,Axel Brandes,Helen Brown,Martina Brueckmann,Hugh Calkins,Barbara Casadei,Andreas Clemens,Harry J.G.M. Crijns,Roland Derwand,Dobromir Dobrev,Michael D. Ezekowitz,Thomas Fetsch,Andrea Gerth,Anne M. Gillis,Michele Massimo Gulizia,Guido Hack,Laurent M. Haegeli,Stéphane N. Hatem,Karl Georg Haeusler,Hein Heidbuechel,Jessica Hernandez-Brichis,Pierre Jaïs,Lukas Kappenberger,J Kautzner,Steven Kim,Karl-Heinz Kuck,Deirdre A. Lane,Angelika Leute,Thorsten Lewalter,Ralf Meyer,Lluís Mont,Gregory Moses,Markus Mueller,Felix Muenzel,Michael Naebauer,Jens Cosedis Nielsen,Michael Oeff,Ali Oto,Burkert Pieske,Ron Pisters,Tatjana S. Potpara,Lars Melholt Rasmussen,Ursula Ravens,James A. Reiffel,Isabelle Richard-Lordereau,Herbert Schaefer,Ulrich Schotten,Wim Stegink,Kenneth M. Stein,Gerhard Steinbeck,Lukasz Szumowski,Luigi Tavazzi,Sakis Themistoclakis,Karen Thomitzek,van Isabelle Gelder,Berndt von Stritzky,Alphons Vincent,David J. Werring,Stephan Willems,Gregory Y.H. Lip,A. John Camm +71 more
TL;DR: opportunities to personalize management of AF in a better manner with a view to improve outcomes by integrating atrial morphology and damage, brain imaging, information on genetic predisposition, systemic or local inflammation, and markers for cardiac strain are identified.